Psychopharmacological and Social Aspects of Schizophrenia: Recent Development *

Abstract

References

Bennett

J. P.

Enna

S. J.

Bylund

D. B.

Gillin

J. C.

Wyatt

R. J.

Snyder

S. H.

(1979) Neurotransmitter receptors in frontal cortex of schizophrenics. Archives of General Psychiatry, 36, 927–934.

Brown

G. W.

Birley

J. L. T.

(1968) Crises and life changes and the onset of schizophrenia. Journal of Health and Social Behaviour, 9, 203–214.

Brown

G. W.

Birley

J. L. T.

Wing

J. K.

(1972) Influence of family life on the course of schizophrenic disorders, British Journal of Psychiatry, 121, 241–258.

Brown

G. W.

Carstairs

G. M.

Topping

G. G.

(1958) The posthospital adjustment of chronic mental patients, Lancet, 2, 685–689.

Brown

G. W.

Bone

Dalison

Wing

J. K.

(1966) Schizophrenia and Social Care. Maudsley Monograph No. 17. Oxford University Press, London.

Brown

G. W.

Harris

T. O.

Peto

(1973) Life events and psychiatric disorders. Part 2: Nature of causal link. Psychological Medicine, 3, 159–176.

Chouinard

Annable

Serrano

Albert

J. M.

Charette

(1975) Amitriptyline-perphenazine interaction in ambulatory schizophrenic patients, Archives of General Psychiatry, 32, 1295–1307.

Collins

A. D.

Dundas

(1967) A double-blind trial of amitriptyline/perphenazine, perphenazine and placebo in chronic withdrawn schizophrenics, British Journal of Psychiatry, 113, 1425–1429.

Crow

T. J.

Johnstone

E. C.

Owen

(1979a) Research on schizophrenia, pp. 1–36 in Recent Advances in Clinical Psychiatry (ed. Granville-Grossman

), Churchill Livingstone, Edinburgh.

10.

Crow

T. J.

Baker

H. F.

Cross

A. J.

Joseph

M. H.

Lofthouse

Longden

Owen

Riley

G. J.

Glover

Kilpatrick

W. S.

(1979b) Monoamine mechanisms in chronic schizophrenia; post-mortem neurochemical findings, British Journal of Psychiatry, 134, 249–256.

11.

Crow

T. J.

Johnstone

E. C.

Owens

D. G. C.

Ferrier

I. N.

Macmillan

J. F.

Parry

R. P.

Tyrrell

D. A. J.

(1979c) Characteristics of patients with schizophrenia or neurological disorder and virus-like agent in cerebrospinal fluid, Lancet, 3, 842–844.

12.

Friedhoff

A. J.

Miller

J. C.

Weisenfreund

(1978) Human platelet MAO in drug free and medicated schizophrenic patients, American Journal of Psychiatry, 135, 952–955.

13.

Gaddum

J. H.

(1954) Drugs antagonistic to 5-hydroxytryptamine, pp. 75–77 in Ciba Foundation Symposium on Hypertension (ed. Wolstenholme

W. G.

), Little, Brown, Boston.

14.

Goldstein

M. J.

Rodnich

E. H.

Evans

J. R.

May

P. R. A.

Steinberg

M. R.

(1978) Drug and family therapy in the aftercare of acute schizophrenics, Archives of General Psychiatry, 35, 1169–1177.

15.

Grinspoon

Ewalt

J. R.

Shader

(1968) Psychotherapy and pharmacotherapy in chronic schizophrenia, American Journal of Psychiatry, 124, 1645–1652.

16.

Gruzelier

J. H.

Hirsch

S. R.

Weller

Murphy

(1979) Influence of D- or DL-propranolol and chlorpromazine on habituation of phasic electrodermal responses in schizophrenia, Acta Psychiatrica Scandinavica, 60, 241–248.

17.

Hanlon

T. E.

Nussbaum

Wittig

Hanlon

D. R.

Kurland

A. A.

(1964) The comparative effects of amitriptyline, perphenazine, and their combination in the treatment of chronic psychotic female patients, Journal of New Drugs, 4, 52–60.

18.

Hirsch

S. R.

Gaind

Rohde

P. D.

Stevens

B. C.

Wing

J. K.

(1973) Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial, British Medical Journal, 1, 633–637.

19.

Hirsch

S. R.

Leff

J. P.

(1975) Abnormalities in Parents of Schizophrenics, Maudsley Monograph No. 22, Oxford University Press, Oxford.

20.

Hogarty

G. E.

Goldberg

S. C.

Schooler

N. R.

Ulrich R. F. and the Collaborative Study Group (1974a) Drug and sociotherapy in the aftercare of schizophrenic patients, Archives of General Psychiatry, 31, 603–608.

21.

Hogarty

G. E.

Goldberg

S. C.

Schooler N. R. and the Collaborative Study Group (1974b) Drug and sociotherapy in the aftercare of schizophrenic patients, III, Adjustment of nonrelapsed patients, Archives of General Psychiatry, 31, 609–618.

22.

Hogarty

G. E.

Schooler

N. R.

Ulrich

R. F.

Mussare

Ferro

Herron

(1979) Fluphenazine and social therapy in the aftercare of schizophrenic patients, Archives of General Psychiatry, 36, 1283–1294.

23.

Jacobs

S. C.

Myers

(1976) Recent life events and acute schizophrenic psychosis; a controlled study. Journal of Nervous and Mental Disease, 162, 75–87.

24.

Jacobs

S. C.

Prusoff

B. A.

Paykel

E. S.

(1974) Recent life events in schizophrenia and depression, Psychological Medicine, 4, 444–453.

25.

Johnstone

E. C.

Crow

T. J.

Frith

C. D.

Carney

M. W. P.

Price

J. S.

(1978a) Mechanism of the antipsychotic effect in the treatment of acute schizophrenia, Lancet, 1, 843–851.

26.

Johnstone

E. C.

Crow

T. J.

Frith

C. D.

Stevens

Kreel

Husband

(1978b) The dementia of dementia praecox, Aeta Psychiatrica Scandinavica, 57, 305–324.

27.

Leff

J. P.

Hirsch

S. R.

Gaind

Rohde

P. D.

Stevens

(1973) Life events and maintenance therapy in schizophrenia, British Journal of Psychiatry, 123, 659–660.

28.

Leff

J. P.

Wing

J. K.

(1971) Trial of maintenance therapy in schizophrenia, British Medical Journal, 3, 559–604.

29.

Linn

M. W.

Caffey

E. M.

Klett

Hogarty

G. E.

Lamb

H. R.

(1979) Day treatment and psychotropic drugs in the aftercare of schizophrenic patients, Archives of General Psychiatry, 36, 1055–1066.

30.

Luborsky

Singer

Luborsky

(1975) Comparative studies of psychotherapies, Archives of General Psychiatry, 32, 995–1008.

31.

May

P. R. A.

(1968) Treatment of Schizophrenia. Science House, New York.

32.

Murphy

D. L.

Wyatt

R. J.

(1972) Reduced platelet monoamine oxidase activity in chronic schizophrenia, Nature, 238, 225–226.

33.

National Institute Of Mental Health Psychopharmacology Service Center Collaborative Study Group (1964) Phenothiazine treatment in acute schizophrenia, Archives of General Psychiatry, 10, 246–261.

34.

Owen

Crow

T. J.

Poulter

Cross

A. J.

Longden

Riley

G. J.

(1978) Increased dopamine-receptor sensitivity in schizophrenia, Lancet, 3, 223–225.

35.

Paykel

E. S.

(1977) The interaction of drugs and psychotherapy. Presented in Workshop in Sociopharmacology: Medicine in a Social Context, World Congress of Mental Health, Vancouver, August 21–26.

36.

Paykel

E. S.

(1978) Contribution of life events to causation of psychiatric illness, Psychological Medicine, 8, 245–253.

37.

Prien

Cole

J. O.

Belkin

(1968) Relapse in chronic schizophrenics following abrupt withdrawal of tranquillising medication: British Journal of Psychiatry, 115, 679–686.

38.

Prien

Levine

Cole

J. O.

(1969) High dose trifluoperazine therapy in chronic schizophrenia, American Journal of Psychiatry, 126, 305–313.

39.

Prusoff

B. A.

Williams

D. H.

Weissman

M. M.

Astrachan

(1979) Treatment of secondary depression in schizophrenia, Archives of General Psychiatry, 36, 569–575.

40.

Shields

(1978) Genetics, pp. 55–87 in Schizophrenia: Towards a New Synthesis (ed. Wing

J. K.

), Academic Press, London.

41.

Stein

Wise

C. D.

(1971) Possible etiology of schizophrenia: progressive damage to the noradrenergic reward system by 6-hydroxydopamine, Science, 171, 1032–1036.

42.

Tarrier

Vaughn

Lader

M. H.

Leff

J. P.

(1979) Bodily reactions to people and events in schizophrenics, Archives of General Psychiatry, 36, 311–315.

43.

Tyrrell

D. A. J.

Crow

T. J.

Parry

R. P.

Johnstone

E. C.

Ferrier

I. N.

(1979) Possible virus in schizophrenia and some neurological disorders, Lancet, 2, 839–841.

44.

Uhlenhuth

E. H.

Lipman

Covi

(1969) Combined pharmacotherapy and psychotherapy: controlled studies, Journal of Nervous and Mental Disease, 148, 52–64.

45.

Vaughn

C. E.

Leff

J. P.

(1976) The influence of family and social factors on the course of psychiatric illness, British Journal of Psychiatry, 129, 125–137.

46.

Venables

P. H.

Wing

J. K.

(1962) Levels of arousal and the subclassification of schizophrenia, Archives of General Psychiatry, 7, 114–119.

47.

Weinberger

D. R.

Torrey

E. F.

Neophytides

A. N.

Wyatt

R. J.

(1979) Structural abnormalities in the cerebral cortex of chronic schizophrenic patients, Archives of General Psychiatry, 36, 935–939.

48.

Wing

J. K.

Brown

G. W.

(1970) Institutionalisation and Schizophrenia. Cambridge University Press, Cambridge.

49.

Wooley

D. W.

Shaw

(1954) A biochemical and pharmacological suggestion about certain mental disorders. Proceedings of the National Academy of Sciences, USA, 40, 228–231.

50.

Wyatt

R. J.

Potkin

S. G.

Murphy

D. L.

(1979) Platelet monoamine oxidase activity in schizophrenia: a review of the data, American Journal of Psychiatry, 136, 377–385.

51.

Yorkston

N. J.

Zaki

S. A.

Malik

M. K. U.

Morrison

R. C.

Havard

C. W. H.

(1974) Propranolol in the control of schizophrenic symptoms, British Medical Journal, 4, 633–635.

52.

Yorkston

N. J.

Zaki

S. A.

Pitcher

D. R.

Gruzelier

J. H.

Hollander

Sergeant

H. G. S.

(1977) Propranolol as an adjunct to the treatment of schizophrenia, Lancet, 3, 575–578.

53.

Yorkston

N. J.

Zaki

S. A.

Weller

M. P. I.

Gruzelier

J. H.

Hirsch

S. R.

(in press) A controlled comparison of DL-propranolol and chlorpromazine following admission for schizophrenia.